In Brief: Immunex Enbrel
Executive Summary
Immunex Enbrel: Company expects FDA to date the rolling Enbrel (TNFR:Fc) BLA submission for rheumatoid arthritis therapy during the second quarter of 1998. The BLA will include preliminary safety data from an open-label trial in 54 juvenile RA patients...